Literature DB >> 20089316

Minocycline attenuates experimental autoimmune encephalomyelitis in rats by reducing T cell infiltration into the spinal cord.

Maria Nikodemova1, Jangeun Lee, Zsuzsanna Fabry, Ian D Duncan.   

Abstract

We investigated the anti-inflammatory effects of minocycline in EAE, an animal model of MS. Minocycline, administered for two weeks after the clinical onset, significantly decreased the cumulative and mean clinical scores of EAE. This was associated with the reduction of both CD4(+) and CD8(+) T cell numbers in the spinal cord and the downregulation of LFA-1 on T cells without affecting the cytokine production profile. The predominant cytokine produced by T cells in the spleen was IFN-gamma whereas in the CNS it was IL-17. Our results indicate that minocycline regulates T cell infiltration into the CNS without modifying the dominant cytokine production. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089316     DOI: 10.1016/j.jneuroim.2009.11.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  14 in total

1.  Minocycline recovers MTT-formazan exocytosis impaired by amyloid beta peptide.

Authors:  Peter Kreutzmann; Gerald Wolf; Kathleen Kupsch
Journal:  Cell Mol Neurobiol       Date:  2010-05-09       Impact factor: 5.046

2.  Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells.

Authors:  Gregory L Szeto; Joel L Pomerantz; David R M Graham; Janice E Clements
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

3.  Bioinformatics analyses reveal age-specific neuroimmune modulation as a target for treatment of high ethanol drinking.

Authors:  Rajiv G Agrawal; Julie A Owen; Patricia S Levin; Aveline Hewetson; Ari E Berman; Scott R Franklin; Ryan J Hogue; Yukun Chen; Chris Walz; Benjamin D Colvard; Jonathan Nguyen; Oscar Velasquez; Yazan Al-Hasan; Yuri A Blednov; Anna-Kate Fowler; Peter J Syapin; Susan E Bergeson
Journal:  Alcohol Clin Exp Res       Date:  2013-10-11       Impact factor: 3.455

4.  Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study.

Authors:  J O Fleming; A Isaak; J E Lee; C C Luzzio; M D Carrithers; T D Cook; A S Field; J Boland; Z Fabry
Journal:  Mult Scler       Date:  2011-03-03       Impact factor: 6.312

5.  11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats.

Authors:  Alexander K Converse; Eric C Larsen; Jonathan W Engle; Todd E Barnhart; Robert J Nickles; Ian D Duncan
Journal:  J Nucl Med       Date:  2011-01-13       Impact factor: 10.057

6.  Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis.

Authors:  Justin E Lengfeld; Sarah E Lutz; Julian R Smith; Claudiu Diaconu; Cameron Scott; Sigal B Kofman; Claire Choi; Craig M Walsh; Cedric S Raine; Ilir Agalliu; Dritan Agalliu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

7.  Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; James B Wade; Douglas P Gibson; Kia Saeian; Jacob A Wegelin; Muhammad Hafeezullah; Debulon E Bell; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Velimir Luketic; Arun J Sanyal
Journal:  Gastroenterology       Date:  2010-09-21       Impact factor: 22.682

Review 8.  Prospects for minocycline neuroprotection.

Authors:  Jennifer M Plane; Yan Shen; David E Pleasure; Wenbin Deng
Journal:  Arch Neurol       Date:  2010-08-09

9.  Minocycline reduces ethanol drinking.

Authors:  R G Agrawal; A Hewetson; C M George; P J Syapin; S E Bergeson
Journal:  Brain Behav Immun       Date:  2011-03-21       Impact factor: 7.217

Review 10.  Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.

Authors:  Shyi-Jou Chen; Yen-Ling Wang; Hueng-Chuen Fan; Wen-Tsung Lo; Chih-Chien Wang; Huey-Kang Sytwu
Journal:  Clin Dev Immunol       Date:  2011-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.